热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　大和发布研报称，维持金斯瑞生物科技（01548）“买入”评级，目标价由28港元下调至25港元，预计金斯瑞生物科技将在2025年实现正盈利，并在往后日子持续录得盈利。该行称，金斯瑞生物科技去年业绩符合预期，期内销售额同比增长6.1%，主要受Genscript

　　Life Science（LSG）推动，其分部收入同比增长10%；净利润为29亿美元，原因是出售Legend的一次性收益；经调整净利润同比增长2.9%。该行提及，上述表现与金斯瑞生物科技早前公布的业绩指引一致。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.